Osimertinib

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

EGFR Gene Amplification

Conditions

EGFR Gene Amplification, EGFR Gene Mutation, Glioblastoma, Recurrent Glioblastoma, Supratentorial Glioblastoma, TP53 Wt Allele

Trial Timeline

Nov 28, 2018 → Jan 31, 2024

NCT ID

NCT03732352

About Osimertinib

Osimertinib is a phase 2 stage product being developed by AstraZeneca for EGFR Gene Amplification. The current trial status is completed. This product is registered under clinical trial identifier NCT03732352. Target conditions include EGFR Gene Amplification, EGFR Gene Mutation, Glioblastoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07295821	Phase 2	Recruiting	Mar 9, 2026	May 30, 2029	Lung Cancer
NCT05629234	Phase 3	Active	May 8, 2023	Feb 22, 2027	Cancer
NCT05546866	Phase 2	Active	Feb 9, 2023	Jun 30, 2029	Non-small Cell Lung Cancer
NCT04908956	Phase 2	Terminated	Aug 4, 2022	Feb 29, 2024	NSCLC Stage IV
NCT05089916	Phase 2	Active	Jan 20, 2022	Mar 1, 2027	NSCLC
NCT05215951	Phase 2	Terminated	Jan 19, 2022	Mar 9, 2023	Lung Cancer
NCT05103605	Pre-clinical	Active	May 12, 2021	Jan 15, 2026	Non Small Cell Lung Cancer
NCT05421936	Pre-clinical	Active	Sep 27, 2020	Sep 1, 2024	Carcinoma, Non-Small-Cell Lung
NCT04391283	Pre-clinical	UNKNOWN	Jul 27, 2020	Dec 1, 2024	Carcinoma, Non-Small-Cell Lung
NCT03853551	Approved	Completed	Apr 18, 2019	Apr 15, 2020	Non Small Cell Lung Cancer (NSCLC)
NCT03769103	Phase 2	Active	Mar 19, 2019	Apr 1, 2025	Lung Cancer Non-small Cell Stage IV
NCT03732352	Phase 2	Completed	Nov 28, 2018	Jan 31, 2024	EGFR Gene Amplification
NCT03667820	Phase 2	Active	Sep 26, 2018	Sep 30, 2027	Non-small Cell Lung Cancer (NSCLC)
NCT03586453	Phase 2	Recruiting	Aug 13, 2018	Mar 1, 2027	Carcinoma, Non-Small-Cell Lung
NCT03433469	Phase 2	Active	Jul 31, 2018	Oct 31, 2026	Stage I Non-Small Cell Lung Cancer
NCT03239340	Phase 2	Completed	May 30, 2018	Sep 19, 2023	EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT03219970	Pre-clinical	Completed	Sep 5, 2017	Oct 28, 2020	Non-small Cell Lung Cancer
NCT03394118	Phase 2	Completed	Aug 11, 2017	Apr 8, 2021	NSCLC
NCT03133234	Pre-clinical	Completed	May 23, 2017	Sep 13, 2017	T790M Positive NSCLC Patients
NCT02841579	Phase 2	Completed	Sep 2, 2016	Feb 14, 2020	Non-Small Cell Lung Cancer

Competing Products

20 competing products in EGFR Gene Amplification

See all competitors

Product	Company	Stage	Hype Score
YH25448	Yuhan	Phase 1/2	41
YH32364	Yuhan	Phase 1/2	41
Datopotamab deruxtecan	Daiichi Sankyo	Pre-clinical	23
HER3-DXd	Daiichi Sankyo	Pre-clinical	23
ASP8273	Astellas Pharma	Phase 2	52
radio-labeled naquotinib + naquotinib	Astellas Pharma	Phase 1	33
erlotinib	Astellas Pharma	Phase 1	33
ASP8273 Capsules + ASP8273 Capsules A	Astellas Pharma	Phase 2	52
famitinib po + HS-10296 po	Jiangsu Hengrui Medicine	Phase 2	52
ABT-414	AbbVie	Pre-clinical	23
AZD9291 40 mg + AZD9291 80 mg	AstraZeneca	Phase 1	33
Osimertinib-based adaptive treatment + Osimertinib 80 MG	AstraZeneca	Phase 2	52
AZD9291 + MEDI4736	AstraZeneca	Phase 3	77
EGFR TKIs (gefitinib, erlotinib, afatinib, et al)	AstraZeneca	Pre-clinical	23
AZD9291	AstraZeneca	Pre-clinical	23
Osimertinib	AstraZeneca	Phase 2	52
Dasatinib + Osimertinib	AstraZeneca	Phase 1/2	41
AZD9291 80mg oral each day	AstraZeneca	Phase 3	77
Tremelimumab + Durvalumab	AstraZeneca	Phase 2	52
AZD3759 + AZD9291	AstraZeneca	Phase 1	33

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved